Biotechnology

Vericel

$41.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.08 (+2.69%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Vericel and other stocks, options, and ETFs commission-free!

About VCEL

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA. The listed name for VCEL is Vericel Corporation Common Stock.

CEO
Dominick C. Colangelo
Employees
241
Headquarters
Cambridge, Massachusetts
Founded
1989
Market Cap
1.85B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
713.41K
High Today
$41.31
Low Today
$39.24
Open Price
$39.68
Volume
574.72K
52 Week High
$41.31
52 Week Low
$6.78

Collections

VCEL Earnings

-$0.21
-$0.07
$0.06
$0.20
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 24, Pre-Market

You May Also Like

SCCO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure